Literature DB >> 16000566

Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype.

Cornelia L Trimble1, Steven Piantadosi, Patti Gravitt, Brigitte Ronnett, Ellen Pizer, Andrea Elko, Barbara Wilgus, William Yutzy, Richard Daniel, Keerti Shah, Shiwen Peng, Chienfu Hung, Richard Roden, Tzyy Choou Wu, Drew Pardoll.   

Abstract

PURPOSE: Persistent infection with oncogenic human papillomaviruses (HPV) plays a central etiologic role in the development of squamous carcinomas of the cervix and their precursor lesions, cervical intraepithelial neoplasias (CIN). We carried out a prospective observational cohort study evaluating known, quantifiable prognostic variables of clinical behavior in women with high-grade cervical lesions. EXPERIMENTAL
DESIGN: Our study cohort included healthy women with high-grade cervical lesions (CIN2/3) with residual visible lesions after colposcopically directed biopsy. We prospectively followed 100 women over 15 weeks before standard resection. HPV typing was done using PCR and a reverse line blot detection method.
RESULTS: The rate of spontaneous histologic regression, defined as (CIN1 or less at resection) was 28%. The overall rate of HPV infection was 100%. HPV16 was identified in 68% of the lesions. Women with HPV16 only were significantly less likely to regress, compared with women with HPV types other than HPV16 (odds ratio, 0.342; 95% confidence interval, 0.117-0.997; P = 0.049). In the cohort with HPV16 only, patients who had an HLA*A201 allele had similar outcomes to those who did not carry A201. However, among patients with HPV types other than HPV16, the HLA*A201 allele interaction was significant; patients with HLA*A201 were the least likely to resolve.
CONCLUSIONS: CIN2/3 lesions associated with HPV16 alone are significantly less likely to resolve spontaneously than those caused by other types. Interactions among HPV type, HLA type, and regression rate support a role for HLA-restricted HPV-specific immune responses in determining disease outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000566      PMCID: PMC3132609          DOI: 10.1158/1078-0432.CCR-04-2599

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.

Authors:  M H Stoler; M Schiffman
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  Interobserver variability in subclassification of squamous intraepithelial lesions: Results of the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology.

Authors:  S L Woodhouse; J F Stastny; P E Styer; M Kennedy; A H Praestgaard; D D Davey
Journal:  Arch Pathol Lab Med       Date:  1999-11       Impact factor: 5.534

3.  A quantification of human cells using an ERV-3 real time PCR assay.

Authors:  C C Yuan; W Miley; D Waters
Journal:  J Virol Methods       Date:  2001-02       Impact factor: 2.014

Review 4.  Homeostatic control of immunity by TCR peptide-specific Tregs.

Authors:  Vipin Kumar
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

5.  The influence of cotinine on interleukin 6 expression in smokers with cervical preneoplasia.

Authors:  W Eppel; C Worda; P Frigo; M Manavi; K Czerwenka
Journal:  Acta Obstet Gynecol Scand       Date:  2000-12       Impact factor: 3.636

6.  Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica.

Authors:  R Herrero; A Hildesheim; C Bratti; M E Sherman; M Hutchinson; J Morales; I Balmaceda; M D Greenberg; M Alfaro; R D Burk; S Wacholder; M Plummer; M Schiffman
Journal:  J Natl Cancer Inst       Date:  2000-03-15       Impact factor: 13.506

7.  Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.

Authors:  M C Bell; P Crowley-Nowick; H L Bradlow; D W Sepkovic; D Schmidt-Grimminger; P Howell; E J Mayeaux; A Tucker; E A Turbat-Herrera; J M Mathis
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

Review 8.  Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials.

Authors:  M Follen; D Schottenfeld
Journal:  Cancer       Date:  2001-05-01       Impact factor: 6.860

9.  Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types.

Authors:  M V Jacobs; J M Walboomers; P J Snijders; F J Voorhorst; R H Verheijen; N Fransen-Daalmeijer; C J Meijer
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

10.  The effect of stopping smoking on cervical Langerhans' cells and lymphocytes.

Authors:  A Szarewski; P Maddox; P Royston; M Jarvis; M Anderson; J Guillebaud; J Cuzick
Journal:  BJOG       Date:  2001-03       Impact factor: 6.531

View more
  77 in total

1.  Preventing cervical cancer globally by acting locally: if not now, when?

Authors:  Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2010-09-30       Impact factor: 13.506

2.  Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.

Authors:  Cornelia L Trimble; Rachael A Clark; Christopher Thoburn; Nicole C Hanson; Jodie Tassello; Denise Frosina; Ferdynand Kos; Jessica Teague; Ying Jiang; Nicole C Barat; Achim A Jungbluth
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

3.  Adherence to conservative management recommendations for abnormal pap test results in adolescents.

Authors:  Rebecca B Perkins; Jennifer R Jorgensen; Molly E McCoy; Sharon M Bak; Tracy A Battaglia; Karen M Freund
Journal:  Obstet Gynecol       Date:  2012-06       Impact factor: 7.661

4.  Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.

Authors:  Matthew P Morrow; Kimberly A Kraynyak; Cornelia L Trimble; Mark L Bagarazzi; Albert J Sylvester; Michael Dallas; Dawson Knoblock; Jean D Boyer; Jian Yan; Russell Vang; Amir S Khan; Laurent Humeau; Niranjan Y Sardesai; J Joseph Kim; Stanley Plotkin; David B Weiner
Journal:  Clin Cancer Res       Date:  2017-10-30       Impact factor: 12.531

5.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

Review 6.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

Review 8.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

9.  Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3.

Authors:  Cornelia L Trimble; Shiwen Peng; Christopher Thoburn; Ferdynand Kos; T C Wu
Journal:  Cancer Immunol Immunother       Date:  2009-12-13       Impact factor: 6.968

10.  Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses.

Authors:  Shao-Ming Wang; Danny Colombara; Ju-Fang Shi; Fang-Hui Zhao; Jing Li; Feng Chen; Wen Chen; Shu-Min Li; Xun Zhang; Qin-Jing Pan; Jerome L Belinson; Jennifer S Smith; You-Lin Qiao
Journal:  Int J Gynecol Cancer       Date:  2013-05       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.